StockData
Inovio Pharmaceuticals, Inc. logo

Inovio Pharmaceuticals, Inc. (INO) stock

INONasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 4/30
$1.63+0.23 (+16.43%)

Close on Nov 17, 2026Market cap $168.54MP/E –Yield –

Inovio Pharmaceuticals total assets

Total assets on the balance sheet at the end of each period.

Inovio Pharmaceuticals's total assets was $49.39M at Jun 30, 2026. For fiscal 2025 it was $74.31M, down 34.4% from the year before. Over ten years it grew -10.0% a year on average. The highest annual figure on record is $539.77M in fiscal 2020.

Annual total assets

PeriodPeriod endValueChange
FY2025Dec 31, 2025$74.31M-34.4%
FY2024Dec 31, 2024$113.20M-33.8%
FY2023Dec 31, 2023$170.95M-51.0%
FY2022Dec 31, 2022$348.53M-29.7%
FY2021Dec 31, 2021$495.94M-8.1%
FY2020Dec 31, 2020$539.77M+275.0%
FY2019Dec 31, 2019$143.95M+9.8%
FY2018Dec 31, 2018$131.11M-30.0%
FY2017Dec 31, 2017$187.24M+7.8%
FY2016Dec 31, 2016$173.71M-18.8%
FY2015Dec 31, 2015$213.84M+62.3%
FY2014Dec 31, 2014$131.79M+49.3%
FY2013Dec 31, 2013$88.29M+95.6%
FY2012Dec 31, 2012$45.14M-26.1%
FY2011Dec 31, 2011$61.11M+9.0%
FY2010Dec 31, 2010$56.07M–

Quarterly total assets

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$49.39M-27.6%
Q1 FY2026Mar 31, 2026$49.78M-43.0%
Q4 FY2025Dec 31, 2025$74.31M-34.4%
Q3 FY2025Sep 30, 2025$69.39M-35.2%
Q2 FY2025Jun 30, 2025$68.24M-49.0%
Q1 FY2025Mar 31, 2025$87.27M-32.4%
Q4 FY2024Dec 31, 2024$113.20M-33.8%
Q3 FY2024Sep 30, 2024$107.06M-44.6%
Q2 FY2024Jun 30, 2024$133.80M-42.6%
Q1 FY2024Mar 31, 2024$129.11M-51.6%
Q4 FY2023Dec 31, 2023$170.95M-51.0%
Q3 FY2023Sep 30, 2023$193.10M-50.7%
Q2 FY2023Jun 30, 2023$233.04M-49.3%
Q1 FY2023Mar 31, 2023$266.58M-40.2%
Q4 FY2022Dec 31, 2022$348.53M-29.7%
Q3 FY2022Sep 30, 2022$391.97M-26.8%
Q2 FY2022Jun 30, 2022$459.40M-22.4%
Q1 FY2022Mar 31, 2022$445.51M-32.0%
Q4 FY2021Dec 31, 2021$495.94M-8.1%
Q3 FY2021Sep 30, 2021$535.76M+22.4%
Q2 FY2021Jun 30, 2021$591.84M+33.5%
Q1 FY2021Mar 31, 2021$654.86M+93.2%
Q4 FY2020Dec 31, 2020$539.77M+275.0%
Q3 FY2020Sep 30, 2020$437.81M+188.9%
Q2 FY2020Jun 30, 2020$443.19M+168.5%
Q1 FY2020Mar 31, 2020$338.92M+77.3%
Q4 FY2019Dec 31, 2019$143.95M+9.8%
Q3 FY2019Sep 30, 2019$151.53M+7.7%
Q2 FY2019Jun 30, 2019$165.07M+10.8%
Q1 FY2019Mar 31, 2019$191.17M+10.1%
Q4 FY2018Dec 31, 2018$131.11M-30.0%
Q3 FY2018Sep 30, 2018$140.70M-30.9%
Q2 FY2018Jun 30, 2018$148.92M-6.3%
Q1 FY2018Mar 31, 2018$173.66M+13.3%
Q4 FY2017Dec 31, 2017$187.24M+7.8%
Q3 FY2017Sep 30, 2017$203.68M+4.7%
Q2 FY2017Jun 30, 2017$158.85M–
Q1 FY2017Mar 31, 2017$153.31M–
Q4 FY2016Dec 31, 2016$173.71M–
Q3 FY2016Sep 30, 2016$194.55M–

More Inovio Pharmaceuticals figures

See a number that looks wrong?